Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC

University of Aarhus logo

University of Aarhus

Status

Terminated

Conditions

Lung Cancer

Treatments

Other: 11C-erlotinib PET/CT

Study type

Interventional

Funder types

Other

Identifiers

NCT01889212
1-10-72-19-12

Details and patient eligibility

About

New treatment strategies have been developed in lung cancer targeting the Epidermal Growth Factor Receptor (EGFR). Patients with an activating mutation in the EGFR have high responds rates to the treatment and should be treated with a EGFR inhibitor as first line of treatment. Some wild type patients do as well respond but selection of these patients is more difficult. Erlotinib has been labeling with 11C and used as a new PET tracer. Accumulation of the tracer (11C-erlotinib) in tumors has showed promising results for selection of responders. The investigators now want to conduct a larger clinical study to evaluate if accumulation of tracer on a pre-treatment 11C-erlotinib PET/CT can predict responds to erlotinib.

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Lung Cancer patients with non-small cell histology and stage IV disease who are candidate for erlotinib treatment as first/ second/ third line of treatment

Exclusion criteria

  • pregnancy
  • severe dyspnoea

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

4 participants in 1 patient group

NSCLC, erlotinib treatment, 11C-erlotinib PET/CT
Experimental group
Treatment:
Other: 11C-erlotinib PET/CT

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems